{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T20:09:13Z","timestamp":1778702953536,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST109-2320-B-009-004-MY3"],"award-info":[{"award-number":["MOST109-2320-B-009-004-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST109-2320-B-009-003-MY3"],"award-info":[{"award-number":["MOST109-2320-B-009-003-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST106-2320-B-009-001-MY3"],"award-info":[{"award-number":["MOST106-2320-B-009-001-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.bcp.2021.114792","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T02:26:27Z","timestamp":1632795987000},"page":"114792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer"],"prefix":"10.1016","volume":"193","author":[{"given":"Su-Pei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Ping","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Jen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chi","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rou-Hsin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuang-Kai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Ying","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7454-3572","authenticated-orcid":false,"given":"Chih-Man","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinpiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinn-Moon","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7389-2455","authenticated-orcid":false,"given":"Mei-Chih","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwok-Kin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jui-I","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2021.114792_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-24223-1_1","article-title":"Lung Cancer Statistics","volume":"893","author":"Torre","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114792_b0010","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.bcp.2021.114792_b0015","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0092-8674(02)00963-7","article-title":"Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains","volume":"110","author":"Ogiso","year":"2002","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bcp.2021.114792_b0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tcb.2013.11.002","article-title":"EGF receptor trafficking: consequences for signaling and cancer","volume":"24","author":"Tomas","year":"2014","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bcp.2021.114792_b0025","doi-asserted-by":"crossref","unstructured":"N.L. Lill, N.I. Sever, Where EGF receptors transmit their signals, Sci Signal 5(243) (2012) pe41.","DOI":"10.1126\/scisignal.2003341"},{"issue":"4","key":"10.1016\/j.bcp.2021.114792_b0030","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1371\/journal.pmed.0040125","article-title":"Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers","volume":"4","author":"Nomura","year":"2007","journal-title":"PLoS Med."},{"issue":"1","key":"10.1016\/j.bcp.2021.114792_b0035","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1634\/theoncologist.9-1-58","article-title":"HER1\/EGFR targeting: refining the strategy","volume":"9","author":"Perez-Soler","year":"2004","journal-title":"Oncologist"},{"issue":"25","key":"10.1016\/j.bcp.2021.114792_b0040","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bcp.2021.114792_b0045","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1634\/theoncologist.8-4-303","article-title":"FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets","volume":"8","author":"Cohen","year":"2003","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.bcp.2021.114792_b0050","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.lungcan.2011.12.014","article-title":"EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment","volume":"77","author":"Brugger","year":"2012","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1016\/j.bcp.2021.114792_b0055","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrclinonc.2010.97","article-title":"Understanding resistance to EGFR inhibitors-impact on future treatment strategies","volume":"7","author":"Wheeler","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114792_b0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10555-010-9201-z","article-title":"Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy","volume":"29","author":"Gazdar","year":"2010","journal-title":"Cancer Metastasis Rev."},{"issue":"2","key":"10.1016\/j.bcp.2021.114792_b0065","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","article-title":"Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"28","author":"Jackman","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114792_b0070","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.cbi.2013.03.011","article-title":"Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells","volume":"203","author":"Yu","year":"2013","journal-title":"Chem. Biol. Interact."},{"issue":"8","key":"10.1016\/j.bcp.2021.114792_b0075","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.bcp.2021.114792_b0080","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1158\/1078-0432.CCR-06-0714","article-title":"Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib","volume":"12","author":"Kosaka","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.bcp.2021.114792_b0085","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nrc2947","article-title":"Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer","volume":"10","author":"Pao","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2021.114792_b0090","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.bcp.2021.114792_b0095","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0897-917","article-title":"A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma","volume":"3","author":"Ambrosini","year":"1997","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.bcp.2021.114792_b0100","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s12015-020-09995-4","article-title":"Emerging importance of survivin in stem cells and cancer: the development of new cancer therapeutics","volume":"16","author":"Warrier","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2021.114792_b0105","first-page":"43","article-title":"Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation","volume":"152","author":"Adida","year":"1998","journal-title":"Am. J. Pathol."},{"issue":"6711","key":"10.1016\/j.bcp.2021.114792_b0110","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/25141","article-title":"Control of apoptosis and mitotic spindle checkpoint by survivin","volume":"396","author":"Li","year":"1998","journal-title":"Nature"},{"issue":"53","key":"10.1016\/j.bcp.2021.114792_b0115","doi-asserted-by":"crossref","first-page":"55875","DOI":"10.1074\/jbc.M407985200","article-title":"Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells","volume":"279","author":"Kuo","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.bcp.2021.114792_b0120","doi-asserted-by":"crossref","first-page":"20267","DOI":"10.1074\/jbc.M312381200","article-title":"Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells","volume":"279","author":"Chao","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2021.114792_b0125","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/sj.cdd.4401416","article-title":"Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L\/TRAIL-induced apoptosis","volume":"11","author":"Chawla-Sarkar","year":"2004","journal-title":"Cell Death Differ."},{"issue":"5","key":"10.1016\/j.bcp.2021.114792_b0130","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.bcp.2005.05.028","article-title":"Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells","volume":"70","author":"Lin","year":"2005","journal-title":"Biochem. Pharmacol."},{"issue":"16","key":"10.1016\/j.bcp.2021.114792_b0135","doi-asserted-by":"crossref","first-page":"14329","DOI":"10.18632\/oncotarget.3685","article-title":"JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bcp.2021.114792_b0140","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/1535-7163.MCT-11-0638","article-title":"Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin","volume":"11","author":"Okamoto","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.bcp.2021.114792_b0145","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1158\/1078-0432.CCR-06-2077","article-title":"Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib","volume":"13","author":"Morgillo","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.bcp.2021.114792_b0150","doi-asserted-by":"crossref","first-page":"10402","DOI":"10.1158\/0008-5472.CAN-10-2438","article-title":"Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations","volume":"70","author":"Okamoto","year":"2010","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.bcp.2021.114792_b0155","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1016\/j.bmcl.2014.09.056","article-title":"Optimization of gefitinib analogues with potent anticancer activity","volume":"24","author":"Yin","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.bcp.2021.114792_b0160","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.taap.2007.04.007","article-title":"Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells","volume":"222","author":"Hsiao","year":"2007","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114792_b0165","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1172\/JCI30446","article-title":"Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas","volume":"117","author":"Li","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bcp.2021.114792_b0170","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ccr.2007.06.005","article-title":"Bronchial and peripheral murine lung carcinomas induced by T790M\u2013L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy","volume":"12","author":"Li","year":"2007","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.bcp.2021.114792_b0175","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/nrm1496","article-title":"Molecular mechanisms of caspase regulation during apoptosis","volume":"5","author":"Riedl","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114792_b0180","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1091\/mbc.01-05-0272","article-title":"Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling","volume":"13","author":"Los","year":"2002","journal-title":"Mol. Biol. Cell"},{"issue":"10","key":"10.1016\/j.bcp.2021.114792_b0185","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/sj.onc.1203429","article-title":"Survivin initiates procaspase 3\/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death","volume":"19","author":"Suzuki","year":"2000","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.bcp.2021.114792_b0190","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/jcp.29956","article-title":"alpha5-nAChR and survivin: Two potential biological targets in lung adenocarcinoma","volume":"236","author":"Zhang","year":"2021","journal-title":"J. Cell. Physiol."},{"issue":"17","key":"10.1016\/j.bcp.2021.114792_b0195","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1158\/0008-5472.CAN-07-1343","article-title":"YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts","volume":"67","author":"Nakahara","year":"2007","journal-title":"Cancer Res."},{"issue":"27","key":"10.1016\/j.bcp.2021.114792_b0200","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1200\/JCO.2008.21.1862","article-title":"Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer","volume":"27","author":"Giaccone","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.bcp.2021.114792_b0205","doi-asserted-by":"crossref","first-page":"11018","DOI":"10.1158\/0008-5472.CAN-05-0491","article-title":"Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase\/AKT signaling pathway in breast cancer cells","volume":"65","author":"Asanuma","year":"2005","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2021.114792_b0210","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/j.1742-4658.2009.07508.x","article-title":"The central role of CDE\/CHR promoter elements in the regulation of cell cycle-dependent gene transcription","volume":"277","author":"Muller","year":"2010","journal-title":"FEBS J."},{"issue":"6","key":"10.1016\/j.bcp.2021.114792_b0215","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ijc.20954","article-title":"Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax","volume":"115","author":"Kawakami","year":"2005","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2021.114792_b0220","doi-asserted-by":"crossref","first-page":"314","DOI":"10.7150\/jca.13332","article-title":"Survivin and tumorigenesis: molecular mechanisms and therapeutic strategies","volume":"7","author":"Chen","year":"2016","journal-title":"J. Cancer"},{"issue":"6","key":"10.1016\/j.bcp.2021.114792_b0225","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.bcp.2021.114792_b0230","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccell.2015.05.012","article-title":"The next wave of EGFR tyrosine kinase inhibitors enter the clinic","volume":"27","author":"Politi","year":"2015","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bcp.2021.114792_b0235","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","article-title":"Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs","volume":"27","author":"Colclough","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bcp.2021.114792_b0240","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10637-016-0350-y","article-title":"AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R\/T790M) in non-small cell lung cancer cells","volume":"34","author":"Ku","year":"2016","journal-title":"Invest. New Drugs"},{"issue":"4","key":"10.1016\/j.bcp.2021.114792_b0245","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.jtho.2015.12.093","article-title":"Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non-small cell lung cancer","volume":"11","author":"Song","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bcp.2021.114792_b0250","doi-asserted-by":"crossref","first-page":"6249829","DOI":"10.1155\/2020\/6249829","article-title":"Pathological mechanistic studies of osimertinib resistance in non-small-cell lung cancer cells using an integrative metabolomics-proteomics analysis","volume":"2020","author":"Ma","year":"2020","journal-title":"J. Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2021.114792_b0255","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3390\/cancers11070947","article-title":"Brexpiprazole, a serotonin-dopamine activity modulator, can sensitize glioma stem cells to osimertinib, a third-generation EGFR-TKI, via survivin reduction","volume":"11","author":"Suzuki","year":"2019","journal-title":"Cancers (Basel)"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221004081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221004081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T19:48:12Z","timestamp":1778701692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221004081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":51,"alternative-id":["S0006295221004081"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114792","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114792","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114792"}}